Key result
Genetic evaluation and testing in pediatric cardiomyopathy is essential for establishing a diagnosis, guiding clinical management, and facilitating family-based risk assessment.
Answers are grounded in this paper and cite their sources.
Comprehensive genetic evaluation in pediatric cardiomyopathy is crucial for clinical diagnosis and may help identify novel therapeutic targets.
Pediatric cardiomyopathies are clinically heterogeneous heart muscle disorders that are responsible for significant morbidity and mortality. Phenotypes include hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, left ventricular noncompaction and arrhythmogenic right ventricular cardiomyopathy. There is substantial evidence for a genetic contribution to pediatric cardiomyopathy. To date, more than 100 genes have been implicated in cardiomyopathy, but comprehensive genetic diagnosis has been problematic because of the large number of genes, the private nature of mutations, and difficulties in interpreting novel rare variants. This review will focus on current knowledge on the genetic etiologies of pediatric cardiomyopathy and their diagnostic relevance in clinical settings. Recent developments in sequencing technologies are greatly impacting the pace of gene discovery and clinical diagnosis. Understanding the genetic basis for pediatric cardiomyopathy and establishing genotype-phenotype correlations may help delineate the molecular and cellular events necessary to identify potential novel therapeutic targets for heart muscle dysfunction in children.
No takes yet. Share an insight, caveat, or question.
Muhammad Tariq (2014) conducted a review in Pediatric cardiomyopathy. Genetic evaluation and testing was evaluated. Genetic evaluation and testing in pediatric cardiomyopathy is essential for establishing a diagnosis, guiding clinical management, and facilitating family-based risk assessment.
Synapse has enriched 10 related papers. Consider them for comparative context: